| Aug 6 |
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024
|
| Jul 8 |
Dianthus (DNTH) Gains 18% in the Past Month: Here's Why
|
| Jun 28 |
Immunovant (IMVT) Down 1.6% Since Last Earnings Report: Can It Rebound?
|
| Jun 28 |
Immunovant: Overvalued Amidst M&A Speculation
|
| Jun 27 |
Immunovant: Next Generation Anti-FcRn Candidate Keeps Hopes Alive
|
| May 31 |
Q4 2024 Roivant Sciences Ltd Earnings Call
|
| May 30 |
After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay
|
| May 30 |
Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus
|
| May 30 |
Immunovant changes up plans for closely watched autoimmune drugs
|
| May 29 |
Immunovant GAAP EPS of -$0.52 misses by $0.08
|
